A citation-based method for searching scientific literature

Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier. Int J Mol Sci 2021
Times Cited: 13







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
23

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
444
23

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K Kashaw, Arun K Iyer. Front Pharmacol 2017
786
15

MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Thijs S Stutvoet, Arjan Kol, Elisabeth Ge de Vries, Marco de Bruyn, Rudolf Sn Fehrmann, Anton Gt Terwisscha van Scheltinga, Steven de Jong. J Pathol 2019
57
15

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid,[...]. Lancet Oncol 2018
346
15

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
15


Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bara, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y Elamin,[...]. J Immunother Cancer 2021
20
15

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
15

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan. Nat Rev Cancer 2019
15

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
66
15

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei. Cancer 2020
109
15

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Jiyun Lee, Bo Mi Ku, Joon Ho Shim, Yoon La Choi, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Jpn J Clin Oncol 2020
9
22

Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Kaname Nosaki, Takashi Kohno, Koji Tsuta,[...]. Lung Cancer 2021
7
28

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Toyoaki Hida, Vamsidhar Velcheti, Karen L Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E Dutcus, Min Ren, Tomohide Tamura. Lung Cancer 2019
45
15

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Lisa M Hess, Yimei Han, Yajun Emily Zhu, Naleen Raj Bhandari, Anthony Sireci. BMC Cancer 2021
10
20

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
228
15

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein, Ludmila Fridel, Tzippy Shochat, Laila C Roisman, Maya Ilouze, Anna Belilovski Rozenblum, Smadar Geva, Alona Zer,[...]. Lung Cancer 2018
24
15

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A Drilon, I Bergagnini, L Delasos, J Sabari, K M Woo, A Plodkowski, L Wang, M D Hellmann, P Joubert, C S Sima,[...]. Ann Oncol 2016
66
15

Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.
Dragana Jovanovic, Marina Roksandic Milenkovic, Jelena Kotur Stevuljevic, Jelena Markovic, Vesna Ceriman, Milica Kontic, Vesna Skodric Trifunovic. J Thorac Dis 2018
23
15

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
Toshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, Takayuki Kosaka, Hirotaka Osada, Kiyoshi Yanagisawa, Tetsuya Mitsudomi, Takashi Takahashi. J Clin Oncol 2006
235
15

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.
Lindsay J Celada, Jonathan A Kropski, Jose D Herazo-Maya, Weifeng Luo, Amy Creecy, Andrew T Abad, Ozioma S Chioma, Grace Lee, Natalie E Hassell, Guzel I Shaginurova,[...]. Sci Transl Med 2018
129
15

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
265
15

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Vyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria-Luisa Alegre, Jason J Luke, Thomas F Gajewski. Science 2018
15

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, L Nezi, A Reuben, M C Andrews, T V Karpinets, P A Prieto, D Vicente, K Hoffman, S C Wei,[...]. Science 2018
15

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P Roberti,[...]. Science 2018
15

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu. Mol Cancer 2018
318
15

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Ayelet Sivan, Leticia Corrales, Nathaniel Hubert, Jason B Williams, Keston Aquino-Michaels, Zachary M Earley, Franco W Benyamin, Yuk Man Lei, Bana Jabri, Maria-Luisa Alegre,[...]. Science 2015
15

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
15

Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor β on cancer cells.
Konrad Kwaśniak, Justyna Czarnik-Kwaśniak, Aleksandra Maziarz, David Aebisher, Kinga Zielińska, Bożenna Karczmarek-Borowska, Jacek Tabarkiewicz. Cent Eur J Immunol 2019
19
7

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses.
Alireza Labani-Motlagh, Mehrnoush Ashja-Mahdavi, Angelica Loskog. Front Immunol 2020
148
7

Protein kinase D3 promotes gastric cancer development through p65/6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 activation of glycolysis.
Jianwei Zhang, Yajing Zhang, Jiaqi Wang, Shuisheng Zhang, Yajie Zhao, Hu Ren, Yunmian Chu, Lin Feng, Chengfeng Wang. Exp Cell Res 2019
8
12


Overexpression of immunosuppressive cytokines is associated with poorer clinical stage of oral squamous cell carcinoma.
Diego Antonio Costa Arantes, Nádia Lago Costa, Elismauro Francisco Mendonça, Tarcília Aparecida Silva, Aline Carvalho Batista. Arch Oral Biol 2016
20
7


B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
Li Li, Jun Zhang, Juan Chen, Zijun Y Xu-Monette, Yi Miao, Min Xiao, Ken H Young, Sa Wang, L Jeffrey Medeiros, Michael Wang,[...]. Blood 2018
54
7

Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Y Maruse, S Kawano, T Jinno, R Matsubara, Y Goto, N Kaneko, T Sakamoto, Y Hashiguchi, M Moriyama, T Toyoshima,[...]. Int J Oral Maxillofac Surg 2018
52
7

The role of CD95 and CD95 ligand in cancer.
M E Peter, A Hadji, A E Murmann, S Brockway, W Putzbach, A Pattanayak, P Ceppi. Cell Death Differ 2015
57
7


MHC class I gene expression and regulation.
S Agrawal, M C Kishore. J Hematother Stem Cell Res 2000
39
7

A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells.
Mónica Kurte, Mercedes López, Adam Aguirre, Alejandro Escobar, Juan Carlos Aguillón, Jehad Charo, Christian G Larsen, Rolf Kiessling, Flavio Salazar-Onfray. J Immunol 2004
54
7

Essentials of oral cancer.
César Rivera. Int J Clin Exp Pathol 2015
335
7

The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.
Wolfgang S Lieb, Cristiana Lungu, Raluca Tamas, Hannah Berreth, Philipp Rathert, Peter Storz, Monilola A Olayioye, Angelika Hausser. Int J Cancer 2020
8
12


Effects of FasL expression in oral squamous cell cancer.
Li Fang, Lin Sun, Fang-Fang Hu, Qiao-Er Chen. Asian Pac J Cancer Prev 2013
14
7

Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines.
Qiusha Tang, Jianqiong Zhang, Bing Qi, Chuanlai Shen, Wei Xie. Arch Med Res 2009
12
8


Macrophages, innate immunity and cancer: balance, tolerance, and diversity.
Alberto Mantovani, Antonio Sica. Curr Opin Immunol 2010
998
7


Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.
Alka Bhatia, Yashwant Kumar. Expert Rev Clin Immunol 2014
78
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.